AI Article Synopsis
- αKlotho is a protein involved in phosphate metabolism, acting alongside FGF23 as a co-receptor to regulate calcium and phosphate levels in the body.
- Soluble αKlotho, released into the bloodstream, has roles both independently and dependently of FGF23, affecting how the body absorbs and excretes phosphate.
- Targeting the αKlotho-FGF23 interaction offers new treatment options for conditions related to phosphate imbalances, including chronic kidney disease.
Article Abstract
Alpha-Klotho is a member of the Klotho family consisting of two other single-pass transmembrane proteins: βKlotho and γKlotho; αKlotho has been shown to circulate in the blood. Fibroblast growth factor (FGF)23 is a member of the FGF superfamily of 22 genes/proteins. αKlotho serves as a co-receptor with FGF receptors (FGFRs) to provide a receptacle for physiological FGF23 signaling including regulation of phosphate metabolism. The extracellular domain of transmembrane αKlotho is shed by secretases and released into blood circulation (soluble αKlotho). Soluble αKlotho has both FGF23-independent and FGF23-dependent roles in phosphate homeostasis by modulating intestinal phosphate absorption, urinary phosphate excretion, and phosphate distribution into bone in concerted interaction with other calciophosphotropic hormones such as PTH and 1,25-(OH)D. The direct role of αKlotho and FGF23 in the maintenance of phosphate homeostasis is partly mediated by modulation of type II Na-dependent phosphate co-transporters in target organs. αKlotho and FGF23 are principal phosphotropic hormones, and the manipulation of the αKlotho-FGF23 axis is a novel therapeutic strategy for genetic and acquired phosphate disorders and for conditions with FGF23 excess and αKlotho deficiency such as chronic kidney disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324980 | PMC |
| http://dx.doi.org/10.1007/s00424-018-2238-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors for radial artery calcification in patients with and without uremia.
BMC Nephrol
January 2025
Department of Nephrology, Southern University of Science and Technology Hospital, Shenzhen, China.
Background: Calcification of the radial artery is one of the main causes of anastomotic stenosis in autogenous arteriovenous fistulas in uremic patients. However, the pathogenesis of calcification is still unknown. This study attempted to screen and validate the risk factors for vascular calcification in patients with uremia.
View Article and Find Full Text PDFHarnessing NLP to Investigate Biomarker Interactions and CVD Risks in Elderly Chronic Kidney Disease Patients.
SLAS Technol
January 2025
Department of General Medicine, The First Afiliated Hospital of Jinan University, Guangzhou, Guangdong, 510000, China. Electronic address:
Chronic kidney disease (CKD) significantly increases the risk of CVD diseases, particularly among elderly patients. Understanding the interaction between several biomarkers and cardiovascular (CVD) risks is crucial for improving patient outcomes and tailoring personalized treatment strategies. There is much more to learn about the intricate relationship between biomarkers and CVD risks in elderly CKD patients.
View Article and Find Full Text PDFNoncanonical RGS14 structural determinants control hormone-sensitive NPT2A-mediated phosphate transport.
Biochem J
January 2025
University of Pittsburgh School of Medicine, Pittsburgh, United States.
The sodium phosphate cotransporter-2A (NPT2A) mediates basal and parathyroid hormone (PTH)- and fibroblast growth factor-23 (FGF23)-regulated phosphate transport in proximal tubule cells of the kidney. Both basal and hormone-sensitive transport require sodium hydrogen exchanger regulatory factor-1 (NHERF1), a scaffold protein with tandem PDZ domains, PDZ1 and PDZ2. NPT2A binds to PDZ1.
View Article and Find Full Text PDFThe effect of sevelamer on serum calcification propensity in patients with chronic kidney disease: the results of a multicentre, double-blind, placebo-controlled, randomized clinical trial.
Clin Kidney J
January 2025
MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
Background: The serum calcification propensity test (or T50 test) might become a standard tool for the assessment of vascular calcification risk and T50 might be a valuable biomarker in clinical trials of treatments intended to slow the progression of vascular calcification. Literature data suggest that non-calcium-containing phosphate binders can influence T50 in chronic dialysed patients. However, it is not clear whether similar interventions are effective in patients at earlier stages of chronic kidney disease (CKD).
View Article and Find Full Text PDFPemigatinib suppresses liver fibrosis and subsequent osteodystrophy in mice.
Hepatol Commun
January 2025
Department of Veterinary Medical Science, Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo, Japan.
Background: Liver fibrosis could lead to serious secondary diseases, including osteodystrophy. The interaction between liver and bone has not been fully elucidated, thus existing therapies for osteodystrophy secondary to liver fibrosis are often ineffective. FGF23 was initially found as an endocrine regulator of phosphate homeostasis, but recently, its involvement in fibrosis has been suggested.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!